 |
|
The
following patents currently provide the foundation of Apath’s
intellectual property position with respect to hepatitis C virus
(HCV), including HCV replicons:
-
U.S. 5,874,565 entitled
Nucleic Acids Comprising a Highly Conserved
Novel 3 Terminal Sequence Element of the Hepatitis C Virus
-
U.S. 6,943,246 B2
entitled
3'Terminal Sequence of Hepatitis C Virus Genome and
Diagnostic and Therapeutic Uses Thereof
-
EP 0856051 entitled
Novel 3’ Terminal Sequence of Hepatitis C Virus Genome and
Diagnostic and Therapeutic Uses Thereof (EP equivalent to
U.S. 5,874,565)
-
AU 713112 entitled
Novel 3’ Terminal Sequence of Hepatitis C Virus Genome and
Diagnostic and Therapeutic Uses Thereof (Australian
equivalent to U.S. 5,874,565)
-
MX 223839 entitled
Novel 3’ Terminal Sequence of Hepatitis C Virus Genome and
Diagnostic and Therapeutic Uses Thereof (Mexican equivalent
to U.S. 5,874,565)
-
IS
123465
entitled
Novel 3’ Terminal Sequence of Hepatitis C Virus Genome and
Diagnostic and Therapeutic Uses Thereof (Israeli equivalent
to U.S. 5,874,565)
-
JP 3911022
entitled
Novel 3’ Terminal Sequence of Hepatitis C Virus Genome and
Diagnostic and Therapeutic Uses Thereof (Japanese equivalent
to U.S. 5,874,565)
-
JP 4031511
entitled
Novel 3’ Terminal Sequence of Hepatitis C Virus Genome and
Diagnostic and Therapeutic Uses Thereof
-
JP 4077016
entitled
Novel 3’ Terminal Sequence of Hepatitis C Virus Genome and
Diagnostic and Therapeutic Uses Thereof
-
U.S.
6,297,003 entitled Methods for the
Detection of a Novel Hepatitis C Virus (HCV) Terminal 3’
Noncoding Region
-
U.S. 6,127,116 entitled
Functional DNA Clone for Hepatitis C Virus
(HCV) and Uses Thereof
-
AU 742175 entitled
Functional DNA Clone for Hepatitis C Virus
(HCV) and Uses Thereof
(Australian equivalent to U.S. 6,127,116)
-
U.S. 6,392,028 B1
entitled Functional DNA Clone for Hepatitis C Virus (HCV) and
Uses Thereof (a continuation patent to U.S. 6,127,116, with
additional claims)
-
U.S. 6,750,009 B1
entitled Multiple Viral Replicon Culture
Systems
-
U.S. 7,049,428 B1
entitled HCV Variants
(Part 1 and 2)
-
AU
2001263407 entitled
HCV Variants
-
AU 2006202902
entitled HCV Variants
-
CA 2283464
entitled Functional DNA Clone
For Hepatitis C Virus (HCV) and Uses Thereof
-
U.S. 7,235,394
entitled Methods for Identifying Adaptive Mutations
- U.S. 26,210,969 A1
US Patent Application entitled Infectious, Chimeric Hepatitis C Virus, Methods of Producing the
Same and Methods of Use Thereof
Additional ex-U.S. equivalents to the above issued patents are
currently pending. The 3’NTR element of the HCV genome as covered
by the ‘565 patent (and its EP counterpart) is essential for
hepatitis-C viral replication, and hence HCV replicon
functioning. The specification of the ‘116 patent describes the
replicon construct and its use.
All worldwide commercial rights under these patents (including the
right to issue sublicenses) have been licensed exclusively to
Apath by Washington University, St. Louis.
Apath currently has additional patent applications pending
covering replicons and/or their use in drug screening:
-
An application with
claims specifically directed to the HCV replicon
-
A method for using
replicons to screen for multiple viruses simultaneously within
the same assay (go to
Multivirus Screening for
additional information)
In the area of RNA virus detection, Apath is the exclusive
licensee (from Washington University, St. Louis) to
U.S. 6,270,958
entitled Detection of Negative Stranded RNA Viruses (go to
RNA
Virus Detection for additional information).
For licensing information relative to the above patents, please
contact;
Robert M. Roth
Phone: (314)
812-8077
Fax: (314)
812-8075
E-mail:
Link
|
|
|
Adobe®
Acrobat
